A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer

Completed · Phase 2

Conditions studied: Breast Cancer

In brief

This multicenter, non-randomized, open-label, phase 2 study is designed to evaluate the safety and efficacy of pertuzumab (Perjeta) in combination with trastuzumab (Herceptin) and anthracycline-based chemotherapy as neoadjuvant treatment in participants with HER2-positive locally advanced, inflammatory, or early-stage breast cancer. Each investigator will choose a treatment regimen (A or B) for all of their participants to follow. Treatment regimen A (for Cohort A) will include dose-dense doxorubicin and cyclophosphamide (ddAC), followed by paclitaxel, with pertuzumab and trastuzumab given from the start of paclitaxel. Treatment regimen B (for Cohort B) will include 5-fluorouracil, epirubicin, and cyclophosphamide (FEC), followed by docetaxel, with pertuzumab and trastuzumab given from the start of docetaxel. Participants in both cohorts will subsequently undergo surgical treatment and then resume pertuzumab and trastuzumab treatment.

Key facts

Study ID

NCT02132949

Run by

Hoffmann-La Roche

People needed

401

Starts

2014-07-14

Expected to finish

2020-08-25

Last updated by the study team

2021-09-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male and female participants with locally advanced, inflammatory, or early-stage, unilateral, and histologically confirmed invasive breast cancer. Participants with inflammatory breast cancer must be able to have a core needle biopsy
• Primary tumor greater than (>) 2 centimeters (cm) in diameter, or > 5 millimeters (mm) in diameter and node-positive
• HER2-positive breast cancer confirmed by a central laboratory
• Availability of tumor tissue specimen
• Baseline LVEF greater than or equal to (>/=) 55%
• Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to (</=) 1
• At least 4 weeks since major unrelated surgery, with full recovery
• Women of childbearing potential and male participants with partners of childbearing potential must agree to use a "highly effective" non-hormonal form of contraception or two "effective" forms of non-hormonal contraception by the patient and/or partner. Contraception must continue for the duration of study treatment and for at least 7 months after the last dose of study treatment

You may not qualify if…

• Metastatic disease (Stage IV) or bilateral breast cancer
• Participants who have had an incisional biopsy of the primary tumor or the primary tumor excised
• Prior breast or non-breast malignancy within 5 years prior to study entry, except for carcinoma in situ and basal cell and squamous cell carcinoma of the skin. Participants with malignancies occurring more than 5 years prior to study entry are permitted if curatively treated
• Any previous systemic therapy (including chemotherapy, immunotherapy, HER2 targeted agents, and antitumor vaccines) for cancer, or radiation therapy for cancer
• Participants with a past history of ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS) are not allowed to enter the study if they have received any systemic therapy for its treatment or radiation therapy to the ipsilateral breast (they are allowed to enter the study if treated with surgery alone)
• High-risk participants who have received chemopreventive drugs in the past are not allowed to enter the study
• Inadequate bone marrow, renal, or liver function
• History or evidence of cardiovascular condition
• Dyspnea at rest or other diseases that require continuous oxygen therapy
• Severe, uncontrolled systemic disease
• Participants with poorly controlled diabetes or with evidence of clinically significant diabetic vascular complications
• Pregnancy or breast-feeding women
• Participants who received any investigational treatment within 4 weeks of study start
• Participants with known infection with human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus
• Current chronic daily treatment with corticosteroids (dose >10 mg methylprednisolone or equivalent [excluding inhaled steroids])
• Known hypersensitivity to any of the study drugs or excipients

Where it is running

• Marin Specialty Care — Greenbrae, California, United States
• California Pacific Medical Center — San Francisco, California, United States
• MedStar Georgetown University Hospital (Lombardi Comprehensive Cancer Center) — Washington D.C., District of Columbia, United States
• Washington Cancer Institute at MedStar Washington Hospital Center. — Washington D.C., District of Columbia, United States
• Cancer Specialists; North Florida ;Jacksonville (AC Skinner Pkwy) — Jacksonville, Florida, United States
• Northwest Georgia Oncology Centers PC - Marietta — Marietta, Georgia, United States
• Berkshire Medical Center — Pittsfield, Massachusetts, United States
• Allina Health, Virginia Piper Cancer Institute — Minneapolis, Minnesota, United States
• Saint Lukes Hospital Cancer Institute — Kansas City, Missouri, United States
• Hackensack University Medical Center — Hackensack, New Jersey, United States
• Regional Cancer Care Associates LLC - Morristown — Morristown, New Jersey, United States
• San Juan Oncology Associates — Farmington, New Mexico, United States
• MSKCC @ Commack — Commack, New York, United States
• MSKCC @ West Harrison — Harrison, New York, United States
• Mount Sinai Beth Israel Comprehensive Cancer Center — New York, New York, United States
• Memorial Sloan Kettering Cancer Center — New York, New York, United States
• MSKC @ Rockville — Rockville Centre, New York, United States
• Mercy Clinic Oklahoma Communties, Inc — Oklahoma City, Oklahoma, United States
• Harrington Cancer Center — Amarillo, Texas, United States
• University of Utah; Huntsman Cancer Hospital — Salt Lake City, Utah, United States
• Blue Ridge Cancer Care — Roanoke, Virginia, United States
• PeaceHealth St. Joseph Cancer Center — Bellingham, Washington, United States
• Northwest Medical Specialties — Tacoma, Washington, United States
• Horizon Health Network — Moncton, New Brunswick, Canada
• University of South Alabama; Mitchell Cancer Institute — Mobile, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.